.png){kind=logo}
Changing the nature of antibiotics, and how we prevent and treat infections, for the better.
founded in 2021, MetalloBio is an antimicrobials development company working on a completely novel paradigm in antibiotics design.
OUR MISSIONWho ARE Metallobio?
MetalloBio is a medical company developing a breakthrough class of broad-spectrum antibacterial agents, representing the first major innovation in the field in nearly 50 years.
We are on a mission to fight the growing threat of ‘superbugs’. We are developing a brand-new class of infection-fighting treatments that work differently than any antibiotics used today.
Our powerful new drug candidates known as KLS-1 Series are specifically designed to treat the most stubborn, complicated infections that standard medicines can no longer keep up with.
We are also working on a second group of compounds, the KLS-2 Series, which have been tuned for use in coatings for medical equipment. By applying these to apparatus such as catheters and joint implants, we can stop infections before they even start.
Our lead treatment KLS-116, named after our late founder Dr Kirsty Louise Smitten, doesn’t just attack a germ in one way, it has a ‘double-strike’ effect. This makes it incredibly hard for bacteria to develop resistance.
Many dangerous infections hide behind a slimy protective shield called a biofilm. While most drugs get bounced off this shield, our compounds are designed to punch right through it and destroy the bacteria hiding inside.
OUR MISSION
MetalloBio is driven to change the nature of antibiotics, and how we prevent and treat infections, for the better.
Making a difference
The modern medicine crisis
Between 1930 and 1962, 20 new types of antibiotics were launched.
In the 50 years since, only two. Because we’ve overused these life-saving drugs, germs like bacteria, viruses, and fungi (otherwise known as microbes) have evolved to resist them causing a process called antimicrobial resistance (AMR).
This means the infections we once easily cured are becoming untreatable as these germs are essentially adapting to survive our treatments, turning into what are often called superbugs.
Most big drug companies stopped looking for new antibiotics years ago due to commercial and clinical reasons.
Now, as our current medicines fail, finding new ways to kill these ‘superbugs’ isn't just a good idea, it’s an urgent necessity to save modern medicine.
Innovative development
Our technology uses a unique metal-based ‘chassis’ rather than traditional chemistry.
This can be adapted in multiple ways to easily custom-build different versions to target specific bacteria.
This approach means that our compounds are stable in extreme heat (up to 350°C) and harsh acidic or basic environments.
They have been shown to kill a wide range of bacteria, including every high-priority ‘superbug’ on the World Health Organisation’s (WHO) ‘ESKAPE’ list.
While lethal to germs, our technology shows very low toxicity to human cells.
Raising awareness
To many, ‘AMR’ might sound like medical jargon, but for the rest of us, it means something much simpler and more frightening: infections we can no longer treat.
Without working antibiotics, even routine surgeries or treating common diseases would become incredibly dangerous, if not impossible.
To tackle this, we are bringing everyone to the table, from drug companies and investors to government leaders and patients.
Our goal is to jump-start the search for the next generation of life-saving medicines.
'I would not be here without those antibiotics'
Olivia Giles was a successful Edinburgh lawyer when a routine afternoon at work became a race against death. Within hours, meningococcal septicaemia had swept through her body and within days she had both hands and both feet amputated. She survived because the right antibiotics reached her in time. Without them, there would have been no recovery, no second chance and no life to rebuild. For millions worldwide, this is already the reality.
READ olivia's STORY HERE.jpeg)
1.2
million
1 patient
dies every 15 minutes
1 death
every 3 seconds
Find us here
Stay connected with MetalloBio as we participate in key industry events and conferences around the globe. These events are crucial platforms for us to share our groundbreaking research, connect with potential partners, and engage with the global community on the urgent issue of antimicrobial resistance (AMR). Explore the list of upcoming events where you can meet our team, learn about our latest innovations, and discover how we are leading the fight against untreatable infections.
See more events >>